Litigation Details for Genentech, Inc. v. Aurobindo Pharma Limited (D. Del. 2019)

Genentech, Inc. v. Aurobindo Pharma Limited (D. Del. 2019)

Docket	1:19-cv-00078	Date Filed	2019-01-14
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	8,013,002
Link to Docket	External link to docket

Details for Genentech, Inc. v. Aurobindo Pharma Limited (D. Del. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-01-14	81	Patent/Trademark Report to Commissioner of Patents	B1 ;7,767,700 B2; 7,816,383 B1 ;7,910,610 B1; 8,013,002 B2 ;8,084,475 B2; 8,318,780 B2 ;8,420,674 B2; …Amended Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,566,729 B1; … 14 January 2019 1:19-cv-00078 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Genentech v. Aurobindo Pharma Patent Litigation: Esbriet, Pirfenidone, and ANDA No. 211500

Last updated: August 22, 2026

Genentech, Inc. v. Aurobindo Pharma Ltd., No. 1:19-cv-00078-RGA, was a Hatch-Waxman action involving Aurobindo's proposed generic version of Genentech's Esbriet product, whose active ingredient is pirfenidone. Genentech asserted U.S. Patent No. 8,609,709, which covered methods of treating idiopathic pulmonary fibrosis with pirfenidone. The District of Delaware found the asserted claims invalid for obviousness. The Federal Circuit affirmed, removing the principal patent barrier to Aurobindo's proposed generic product.[1][2]

What drug and patent were involved in Genentech v. Aurobindo?

The case involved Esbriet, a pirfenidone product approved by the U.S. Food and Drug Administration for the treatment of idiopathic pulmonary fibrosis, or IPF. Aurobindo filed an abbreviated new drug application seeking approval for generic pirfenidone capsules.

Item	Detail
Brand drug	Esbriet
Active ingredient	Pirfenidone
Therapeutic area	Idiopathic pulmonary fibrosis
Brand owner	Genentech, Inc.
Proposed generic manufacturer	Aurobindo Pharma Ltd. and related entities
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:19-cv-00078-RGA
Filing year	2019
Primary patent	U.S. Patent No. 8,609,709
Patent subject matter	Methods of treating fibrotic disease, including IPF, with pirfenidone
Procedural basis	Hatch-Waxman litigation arising from an ANDA Paragraph IV certification

Genentech acquired rights to pirfenidone through its acquisition of InterMune. Esbriet was approved in the United States in 2014. The patent dispute arose after Aurobindo notified Genentech that its ANDA included a Paragraph IV certification challenging the validity, enforceability, or infringement of the listed patent.[1]

What patent did Genentech assert against Aurobindo?

Genentech asserted U.S. Patent No. 8,609,709, titled "Methods of Treating Fibrotic Diseases." The patent covered methods involving administration of pirfenidone to patients with fibrotic diseases, including IPF.

The relevant claims focused on treatment regimens rather than a new chemical entity. The litigation therefore turned on whether the claimed clinical use and dosing approach would have been obvious in view of earlier publications concerning pirfenidone, pulmonary fibrosis, and clinical development of the drug.

The patent had an expiration date in the mid-2020s, subject to patent-term adjustment and regulatory exclusivity considerations. The case did not turn on a claim that Aurobindo had copied the pirfenidone molecule. The dispute concerned whether Aurobindo's proposed labeling and product approval would induce infringement of Genentech's method claims under 35 U.S.C. § 271(e)(2).

Was U.S. Patent No. 9,018,311 involved?

Genentech's broader Esbriet patent estate included other method-of-use and formulation-related patents, including U.S. Patent No. 9,018,311. The reported appellate decision in this action centered on U.S. Patent No. 8,609,709. Patent scope and asserted claims varied across the separate generic-company cases involving pirfenidone.

The litigation should therefore be analyzed by defendant and docket rather than by treating every Esbriet patent case as a single consolidated proceeding.

What was Aurobindo's Paragraph IV challenge?

Aurobindo's ANDA contained a Paragraph IV certification directed to the listed Esbriet patent. A Paragraph IV certification states that the relevant patent is invalid, unenforceable, or will not be infringed by the proposed generic product.

Genentech responded by filing suit within the statutory 45-day period. The filing triggered the Hatch-Waxman automatic stay, preventing FDA approval of the ANDA for up to 30 months unless the stay was lifted earlier by a court order or other statutory event.[3]

The central issues were:

1. Whether Aurobindo's proposed generic labeling would induce infringement of the patented treatment method.
2. Whether the asserted claims were invalid for obviousness under 35 U.S.C. § 103.
3. Whether the prior art disclosed or suggested the claimed use of pirfenidone for IPF.
4. Whether a skilled person would have had a reasonable expectation that the treatment would work.
5. Whether the claims provided an inventive clinical dosing regimen or merely claimed an expected use of a known compound.

How did the District of Delaware rule?

The District of Delaware held the asserted claims of the '709 patent invalid for obviousness. The court concluded that the prior art provided sufficient motivation to investigate pirfenidone for IPF and that the claimed treatment did not reflect an inventive advance over the existing technical record.[1]

The court's analysis addressed the standard Graham factors:

Obviousness factor	Court's treatment
Scope and content of prior art	Prior publications disclosed pirfenidone, antifibrotic activity, and treatment of fibrotic lung disease
Differences from claimed invention	The claimed regimen was directed to the clinical use of a known compound for IPF
Level of ordinary skill	Skilled researchers had relevant experience in pulmonary disease, fibrosis, and drug development
Motivation to combine or pursue	The record supported investigation of pirfenidone for IPF
Reasonable expectation of success	The court found the evidence sufficient to support a reasonable expectation of success
Objective indicia	Genentech's evidence of commercial success and clinical results did not overcome the obviousness showing

The decision was significant because the patent's claims were directed to a commercially important approved use of pirfenidone. Invalidating the method patent eliminated the primary basis for blocking FDA approval of an ANDA that otherwise met the drug-product requirements.

What did the Federal Circuit decide?

The Federal Circuit affirmed the District of Delaware's obviousness determination. The appellate court rejected Genentech's arguments that the district court had applied an incorrect obviousness framework or failed to give appropriate weight to evidence supporting nonobviousness.[2]

The Federal Circuit's decision preserved the following conclusions:

• Pirfenidone was known before the patent's priority date.
• The prior art provided a reason to study pirfenidone for pulmonary fibrosis.
• The asserted claims did not require an inventive technical step beyond the prior-art disclosure.
• Evidence of commercial success and clinical efficacy did not independently establish nonobviousness.
• The district court's factual findings were not clearly erroneous.

The appellate ruling made the invalidity judgment final for the claims at issue in that appeal, subject to any later rehearing or Supreme Court proceedings.

What was the litigation timeline?

Date	Event
2019	Genentech filed the Hatch-Waxman complaint in the District of Delaware
2019-2021	Claim construction, fact discovery, expert discovery, and pretrial proceedings
2022	District court entered judgment holding the asserted '709 patent claims invalid for obviousness
2023	Federal Circuit affirmed the judgment
After affirmance	The invalidated patent no longer provided a judicial basis to block Aurobindo's ANDA on those claims

The litigation did not produce a reported finding that Aurobindo's product infringed a valid and enforceable patent. The case ended with a defense judgment based on invalidity.

Did Genentech and Aurobindo settle?

The reported disposition was an adjudicated invalidity judgment followed by Federal Circuit affirmance, not a publicly reported patent settlement. No settlement agreement appears to have supplied the operative resolution of the claims at issue in the appellate decision.

This distinguishes the case from many ANDA disputes in which the brand company and generic applicant settle through a delayed-entry agreement, license, or authorized-generic arrangement. Here, the decisive event was the invalidation of the asserted patent claims.

What was the FDA and Orange Book status of Esbriet?

Esbriet was FDA-approved for IPF and its relevant patents were listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book.[3]

The FDA regulatory consequences were separate from the patent merits:

• The FDA evaluated Aurobindo's ANDA for pharmaceutical equivalence, bioequivalence, manufacturing, labeling, and other statutory requirements.
• The Paragraph IV litigation affected the patent-based approval bar.
• The court's invalidity judgment removed the asserted '709 patent as a basis for continuing to block approval.
• FDA approval did not depend on the court finding that the generic product was clinically superior or identical in every respect to Esbriet.
• Any remaining listed patents, pediatric exclusivity, regulatory exclusivity, or separate litigation had to be assessed independently.

For pirfenidone, biologic-biosimilar rules were irrelevant. Esbriet is a small-molecule drug, so generic competition proceeded through the ANDA pathway rather than the Biologics Price Competition and Innovation Act pathway.

What generic-entry risks existed after the ruling?

The judgment materially reduced Genentech's patent-based control over U.S. pirfenidone entry. The main risk categories after the Federal Circuit decision were regulatory and commercial rather than infringement risk under the invalidated claims.

Regulatory risk

Aurobindo still needed FDA approval of the ANDA and compliance with FDA manufacturing and labeling requirements. Court victory did not itself grant marketing approval.

Remaining-patent risk

Other Esbriet-related patents could create separate litigation exposure if they remained listed and applicable to the proposed product or labeling. A generic entrant also had to evaluate formulation, dosing, manufacturing, and method-of-use patents separately from the '709 patent.

Launch risk

An Aurobindo launch could face:

• appeal-related stays or procedural delays;
• a later action involving a different patent;
• FDA deficiencies or approval delays;
• commercial contracting and reimbursement barriers;
• competition from other pirfenidone applicants.

The invalidity ruling nonetheless changed the expected launch profile from a potentially patent-blocked product to one with a substantially lower litigation barrier.

How strong was Genentech's Esbriet patent estate?

The Esbriet estate had commercial value because it protected an approved indication for a drug whose composition itself was known. Its strength depended heavily on method-of-use claim validity.

The Aurobindo decision exposed a structural weakness in that strategy: treatment claims directed to applying a known compound to a related disease can be vulnerable when prior art supplies a reason to investigate the compound and a reasonable expectation of success.

Patent-estate dimension	Assessment after Aurobindo
New chemical entity protection	Limited relevance because pirfenidone was known
Method-of-use protection	Vulnerable where prior art connected pirfenidone with fibrotic disease
Formulation protection	Dependent on separate claim language and patent-specific validity
Manufacturing protection	Potentially relevant only if the generic process practiced the claimed steps
Biosimilar protection	Not applicable
Litigation leverage	Reduced after affirmance of '709 invalidity
Generic-entry exposure	Increased materially

What was the commercial impact for Genentech?

The decision exposed Genentech to generic erosion of Esbriet revenue once Aurobindo and other applicants obtained FDA approval and entered the market. The precise revenue effect depended on the number of approved generic suppliers, launch timing, payer substitution, rebates, and the survival of other patents.

The case had greater commercial importance because Esbriet was an approved chronic therapy for IPF, a market in which generic substitution can materially affect net pricing. Invalidation of the principal method patent reduced the ability to preserve branded pricing through patent-based exclusion.

No reliable case-specific revenue figure should be attributed to this docket alone. Genentech's public reporting generally aggregates products and does not isolate the revenue impact of one defendant's ANDA litigation.

What manufacturing and intellectual-property barriers remained?

The invalidity judgment did not eliminate all barriers to generic pirfenidone entry. Aurobindo still had to demonstrate:

• pharmaceutical equivalence to the reference-listed drug;
• bioequivalence;
• acceptable impurity and stability profiles;
• compliant manufacturing controls;
• validated analytical methods;
• approved labeling;
• compliance with FDA inspection and post-approval obligations.

From an IP perspective, the remaining review areas included formulation patents, process patents, crystalline-form patents, dosing patents, and patents covering specific patient populations. A generic applicant could also face a new suit if Genentech asserted a different unexpired patent after an amended ANDA or a change in product design.

Key Takeaways

• Genentech's case against Aurobindo concerned generic pirfenidone for Esbriet.
• The principal patent was U.S. Patent No. 8,609,709.
• The District of Delaware held the asserted claims invalid for obviousness.
• The Federal Circuit affirmed the judgment.
• The case was resolved through adjudicated invalidity, not a publicly reported settlement.
• The ruling weakened Genentech's patent-based exclusion for generic Esbriet.
• Biosimilar law was not relevant because pirfenidone is a small-molecule drug.
• Remaining Esbriet patents and FDA requirements had to be evaluated separately.
• The decision increased the likelihood of generic price and market-share erosion.

FAQs About Genentech v. Aurobindo

What ANDA did Aurobindo file for the Esbriet litigation?

Aurobindo filed an ANDA seeking approval for generic pirfenidone, the active ingredient in Esbriet. The litigation followed Aurobindo's Paragraph IV certification against Genentech's listed patent.

Did Genentech win the patent case against Aurobindo?

No. The district court held the asserted patent claims invalid for obviousness, and the Federal Circuit affirmed that result.

Can Aurobindo launch generic pirfenidone immediately after the court ruling?

Court victory removes the asserted patent barrier but does not itself guarantee immediate launch. FDA approval, statutory exclusivity, other patents, and commercial launch conditions remain relevant.

Was Esbriet protected by a biologic exclusivity period?

No. Esbriet is a small-molecule drug. Its generic pathway is an ANDA under the Hatch-Waxman Act, not a biosimilar application under the BPCIA.

Does the Aurobindo ruling invalidate every Esbriet patent?

No. The judgment applies to the asserted claims and patent at issue in the case. Other Esbriet patents require separate validity, infringement, expiration, and Orange Book analysis.

References

1. Genentech, Inc. v. Aurobindo Pharma Ltd., No. 1:19-cv-00078-RGA, U.S. District Court for the District of Delaware, judgment and post-trial opinions (2022).

2. Genentech, Inc. v. Aurobindo Pharma Ltd., U.S. Court of Appeals for the Federal Circuit, appellate decision affirming invalidity of U.S. Patent No. 8,609,709 (2023).

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.